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Abstract
Expression of inducible nitric oxide synthase (iNOS) is generally accompanied by a parallel upregulation in L-arginine transport
which is dependent, at least in part, on the synthesis of new carrier proteins. It is not clear however whether the induction of iNOS
and its subsequent utilisation of L-arginine for NO synthesis contribute to the enhancement in L-arginine transport rates observed
following induction of cells with pro-inXammatory mediators. To address this issue, we have transfected an iNOS construct in a
pEGFP-N1 vector into HEK-293 cells and investigated the eVects this has on L-arginine transport. The expression of iNOS through
transfection resulted in the production of signiWcant quantities of NO as detected by the standard Griess assay. Under these condi-
tions, the transport of L-arginine was found to be unaltered, with rate of uptake being comparable in both transfected and non-trans-
fected cells. Characterisation of the transporter(s) involved with uptake of L-arginine revealed features characteristic of the classical
cationic amino acid transport system y+. Further analysis of the expression proWle of the cationic amino acid transporter (CAT)
involved revealed the presence of transcripts for CAT-1 and AT-2B. These data demonstrate that iNOS activity does not drive or
enhance L-arginine transport despite the fact that HEK-293 cells transport L-arginine via the CATs, including CAT-2B which is
thought to be critical for supply of substrate to iNOS.
 2004 Published by Elsevier Inc.
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COExpression of inducible nitric oxide synthase (iNOS)in various cells and tissues is associated with the over-production of nitric oxide (NO) which although criticalfor immune defences also functions as an important
mediator of inXammatory responses with detrimental
consequences. For instance, iNOS produced NO is
believed to be responsible for the systemic hypotension
seen in septic shock [1–3] and has been implicated in the
pathogenesis of several other inXammatory diseases,
* Corresponding author. Fax: +01707 285 046.
E-mail address: a.baydoun@herts.ac.uk (A.R. Baydoun).1089-8603/$ - see front matter  2004 Published by Elsevier Inc.
doi:10.1016/j.niox.2004.11.001including asthma [4] and inXammatory bowel disease [5].
Once expressed, synthesis of NO by iNOS is critically
dependent on the availability and transport of L-arginine
[6–10]. The induction of iNOS by pro-inXammatory
mediators is accompanied by a parallel upregulation in
L-arginine transport [7,11–13] which is due at least in
part to enhanced expression of transcripts for cationic
amino acid transporters (CATs), including CAT-1, 2B,
and potentially 2A [14,15]. This parallel upregulation in
CAT expression and activity provides a mechanism for
sustaining substrate supply during enhanced synthesis of
NO by iNOS. It is not known, however, whether the
expression of iNOS and the subsequent enhanced utilisa-
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tion of L-arginine by this enzyme directly regulate CAT
expression and function. One report in the literature has
indicated that inhibition of iNOS activity using either 2-
amino-5,6-dihydro-6-methyl-4H-1,3-thiazine (AMT), a
potent and selective inhibitor of iNOS [16] or S-ethyl-
isothiourea, a potent but non-selective NOS inhibitor
[17], abolished LPS-induced L-arginine transport [18].
The same group has also demonstrated that expression
of both iNOS and CAT-2B mRNA may be downregu-
lated after prolonged (20 h) exposure of rat alveolar
macrophages to dexamethasone. These eVects were
accompanied by corresponding decreases in both LPS-
stimulated nitrite production and L-[3H]arginine trans-
port, suggesting a parallel regulation of the expression
and function of iNOS and CAT-2B, at least in rat alveo-
lar macrophages [19]. These Wnding are, however, at
odds with previous studies in the murine macrophage
J774 cell line [20] and in rat cultured aortic smooth mus-
cle cells [13,21] in which dexamethasone selectively
blocked iNOS expression whilst having no eVect on
induced L-arginine transport, suggesting that upregula-
tion of transport may be independent of iNOS activity.
These studies did not however take into account the fact
that other pathways which utilise L-arginine may also be
switched on in activated cells, thus masking any direct
coupling between utilisation of L-arginine by iNOS and
the subsequent regulation of transport that may occur as
a consequence of the activity of this enzyme.
To determine unequivocally whether CAT function is
inXuenced by the activity of iNOS we therefore deliber-
ately chose to use an experimental system in which iNOS
could be expressed and was fully active in cells in the
absence of pro-inXammatory stimuli. Transient iNOS
expression was therefore induced by transfection in
human embryonic kidney-293 (HEK-293 cells). These
cells can be easily transfected but do not express endoge-
nous iNOS or show any upregulation in CAT activity
following exposure to the standard cocktail of bacterial
lipopolysaccharide (LPS) and cytokines generally used
to induce these pathways in other cells (unpublished
observations). In parallel studies, the characteristics of L-
arginine transport have been fully investigated and the
nature of the transporters involved with L-arginine
uptake established. These studies are essential since very
little is currently known about the mechanism of entry of
L-arginine into HEK293 cells. Moreover, the transport-
ers expressed may potentially determine the manner in
which NO synthesis is regulated in these cells.
Experimental procedure
Materials
Tissue culture reagents were obtained from Invitro-
gen (Paisley, UK). Other reagents used were: SMARTTE
D P
RO
OF
RACE cDNA AmpliWcation Kit (BD Biosciences Clon-
tech, Cowley, UK); Eukaryotic TOPO TA Cloning Kit
and competent Escherichia coli (Invitrogen, Paisley,
UK); PCR primers (MWG Biotech, Milton Keynes,
UK); Restriction enzymes and T4 DNA ligase (Pro-
mega, Southampton, UK); Taq DNA Polymerase, M-
MLV reverse Transcriptase, and dNTP (Invitrogen,
Paisley, UK); Plasmid miniprep and maxiprep kits
(Qiagen, Crawley, UK); anti-iNOS and anti-GFP mono-
clonal antibodies (BD Biosciences Clontech, Cowley,
UK). L-[2,3-3H]arginine (36.1 Ci/mmol) was obtained
from New England Nuclear (Dreieich, Germany).
Bicinchoninic acid (BCA) protein assay reagent was
from Pierce (Perbio Science UK, Cheshire, UK).
GW274150 was a gift from GlaxoSmithKline (Steve-
nage, UK). All other chemicals were obtained from
Sigma or BDH and were of the highest analytical grade
obtainable.
Cell culture
HEK-293 cells were maintained in Dulbecco’s modi-
Wed Eagle’s medium (DMEM) supplemented with peni-
cillin (100 U ml¡1), streptomycin (100g ml¡1), and 10%
foetal bovine serum. Cells were harvested by trypsinisa-
tion and passaged every 5 days by dilution of a suspen-
sion of the cells 1:4 in fresh medium.
RNA isolation
Total cellular RNA was isolated from the cultured
cells using RNA STAT-60 (Biogenesis, Poole, UK)
according to the manufacturer’s protocol. The concen-
tration of RNA solutions was determined spectrophoto-
metrically and the quality veriWed by visualisation of 28S
and 18S rRNA bands after electrophoresis through a 1%
ethidium bromide stained agarose gel.
Construction of iNOS-pEGFP-N1 Plasmid
Total RNA was extracted from rat (Wistar) cultured
aortic smooth muscle cells activated with bacterial lipo-
polysaccharide (LPS; 100g ml¡1) and interferon-
(IFN-; 50 U ml¡1) for 24 h. The Wrst strand cDNA was
synthesised from 1g total RNA using the Clontech
SMART system (BD Biosciences Clontech, Cowley,
UK) and an iNOS gene-speciWc reverse primer (5-GAG
TCT TGT GCC TTT GGG CT-3) based on a pub-
lished rat iNOS cDNA sequence (Accession No.:
X76881). The cDNA products were subsequently ampli-
Wed by PCR using the SMART RACE cDNA AmpliW-
cation Kit together with the above reverse primer,
lacking the nucleotide sequence for the iNOS stop
codon. To facilitate translation initiation and enhance
iNOS-GFP expression levels, a modiWed iNOS forward
primer was designed with a Kozak consensus sequence
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introduced around the initiation codon of iNOS (5-
CAC CGC CAT GGC TTG CCC CTG GAA-3). A
3.449 kb cDNA fragment ampliWed was ligated into
pcDNA3.1 using the Eukaryotic TOPO TA Cloning Kit.
After transformation into E. coli, a mini-preparation of
the plasmid was made and the puriWed cDNA sequenced
using a Beckman Coulter CEQ2000XL Sequencer. The
iNOS-GFP expression vector was subsequently con-
structed by digesting pcDNA 3.1 harbouring the iNOS
cDNA with HindIII and SacII, and then subcloning the
restricted iNOS cDNA from pcDNA3.1 into the HindIII
and SacII sites of the pEGFP-N1 vector. The iNOS
sequence was fused at its C terminal to GFP and was
driven directly by the CMV promoter of the plasmid.
Transfection of HEK293 cells with iNOS-pEGFP-N1
ConXuent monolayers of HEK-293 cells in T75 tissue
culture Xasks were trypsinised and plated into 24-well
plates at a seeding density of 2 £ 104 cells per well. Cells
were allowed to grow to 60% conXuency prior to trans-
fecting with iNOS-pEGFP-N1 using an 51 integrin-
binding polycationic peptide ([K]16GACRRETAWA
CG; Peptide 6) [22]. For optimum transfection eYciency,
conditions previously described [22] were adhered to.
BrieXy, culture medium was removed from wells and the
adherent cells washed twice with PBS. 0.5 ml of transfec-
tion complex in Opti-MEM I medium containing lipo-
fectin (0.75l), plasmid (1g), and peptide 6 (4g) was
then added to each well. Cells were incubated for a fur-
ther 3 h at 37 °C, after which the medium was removed,
replace with normal culture medium containing 10%
FCS and incubated in a tissue culture incubator at 37 °C
for 6–48 h before determining accumulated nitrite levels
in the culture medium as described below. In parallel
experiments cells were also incubated with the potent
and highly selective iNOS inhibitor GW274150 (S-[2-[(1-
iminoethyl)amino]ethyl]-L-homocysteine) to inhibit NO
production [23]. In control experiments cells were trans-
fected with either empty vector or pEGF-N1 vector
alone. Transfected cells were routinely visualised using a
Nikon EFD 3 Labophot-2 Xuorescence microscope and
the transfection eYciency determined from the propor-
tion of green Xuorescing cells. The estimated transfection
eYciency generally obtained with the above protocol
was between 60 and 70%. Batches of cells showing <50%
transfection were discarded. There was no detectable
Xuorescence in cells transfected with the empty non-
GFP vector alone.
Western blot analysis of iNOS expression
Western blotting was carried out as described previ-
ously [24]. Cell lysates (20g protein per lane) were sepa-
rated by SDS–PAGE electrophoresis, transferred onto
PVDF membrane (Sigma–Aldrich, Poole, UK) andTE
D P
RO
OF
blocked for 2 h in 100 mM NaCl, 10 mM Tris, 0.1% (v/v)
Tween 20, pH 7.4 (STT), containing 5% (w/v) non-fat
milk. Membranes were then incubated overnight with
either a monoclonal anti-iNOS (1:2500 dilution) or anti-
GFP (1:1000 dilution) antibody in STT containing 5%
(w/v) non-fat milk). Blots were washed with STT
(6 £ 5 min) and incubated with a 1:10,000 dilution of
horseradish peroxidase-conjugated goat anti-mouse
antibody for 1 h. Following further washing (6 £ 5 min)
in STT, immunoreactive bands were visualised using
ECL detection System (Amersham–Pharmacia, Buck-
inghamshire, UK).
Measurement of nitrite formation
Measurement of nitrite production as an assay of NO
release was carried out as described previously [24] using
the Griess reaction with sodium nitrite as standard [25].
Measurement of L-arginine transport
Unidirectional transport of L-arginine was measured
in cell monolayers as described previously [20]. Cells
were rinsed twice with a modiWed Hepes-buVered Krebs
solution (composition (mM): NaCl, 131; KCl, 5.5;
MgCl2, 1; CaCl2, 2.5; NaHCO3, 25; NaH2PO4, 1; D-glu-
cose, 5.5; Hepes, 20; pH 7.4) at 37 °C. Uptake was initi-
ated by adding 50l of Krebs containing either 100M
or increasing concentrations (10–1000M) of L-[3H]argi-
nine (2Ci ml¡1) to each well and inXux measured over
1 min. The eVects of pH on transport were examined in
Krebs solution with pH values ranging between pH 6
and 7.4. In parallel experiments, the sodium-dependency
of transport was examined in modiWed buVer in which
NaCl, NaHCO3, and NaH2PO4 were replaced with cho-
line chloride, choline bicarbonate, and KH2PO4, respec-
tively. Uptake of L-[3H]arginine was terminated by
placing plates on ice and rinsing cells twice with 200l
ice-cold Krebs containing 10 mM unlabelled L-arginine.
Cell protein was determined using bicinchoninic acid
(BCA) protein assay reagent following the manufac-
turer’s protocol. Radioactivity (dpm) in cell lysates was
measured by liquid scintillation counting. Transport was
expressed in pmolg protein¡1 min¡1.
ProWle of CAT expression in HEK-293 cells
The identiWcation of the CATs expressed in HEK-293
cells was determined by RT-PCR. The Wrst-strand
cDNA was synthesised from 2g total RNA using 0.5l
(250 ng) random hexamer primers, 1l M-MLV reverse
transcriptase (200 U/l), 1l dNTP (10 mM), 4l of 5£
Wrst-strand buVer, 2l dithiothreitol (0.1 M), 1l RNase-
OUT (40 U/l), and 9l sterile distilled water. The reac-
tion was allowed to proceed according to the supplier’s
recommendation (Invitrogen, Paisley, UK) for M-MLV
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reverse transcreptase. The cDNA product was ampliWed
by PCR using CAT-speciWc primers designed from Gen-
bank sequences for human CAT-1 (Accession No.:
NM_003045), CAT-2 A (Accession No.: U76368), and
CAT-2B (Accession No.: D29990). The following primer
pairs were used: hCAT-1 (656 bp), 5-TCG GCC ATG
GTC AAC AAA AT-3 and 5-TCA AAG AGG AAG
GCC ATC ACA-3; hCAT-2A (599 bp), 5-GAG TCT
GCT TGG GTG AAT AAA-3 and 5-GAC TGC CTC
TTA CTC ACT CT-3; and hCAT-2B (642 bp), 5-GAG
TCT GCT TGG GTG AAT AAA-3 and 5-AGC TGC
CAC TGC ACC CGA TGA-3. AmpliWcation was car-
ried out in a Techne touchgene programmable thermal
cycler (Techne, Cambridge, UK) using Taq DNA poly-
merase (0.5 U). The reaction mixture (0.5l of a 10M
stock of each primer, 0.5l of dNTP (10 mM), 2.5l of
10£ PCR buVer, 0.75l of 50 mM MgCl2, and 19.75l
sterile distilled water) was initially heated to 94 °C for
2 min, followed by 33 cycles under the following condi-
tions: denaturing at 94 °C for 30 s, annealing at 55 °C for
40 s, extension at 72 °C for 40 s, and a Wnal extension step
at 72 °C for 5 min. Ten microliters of the PCR product
was used for DNA electrophoresis on a 1% agarose gel,
stained with ethidium bromide, and documented using a
Bio-Rad imager system.
Statistics
All values are means § SE of measurements in at least
three diVerent cell cultures with two replicates per exper-
iment. ANOVA was used to determine statistical signiW-
cance between paired values with the overall conWdence
levels set at 95% (0.05).
Results
Cloning, sequence, and analysis of iNOS cDNA
A 3.449 kb cDNA fragment was ampliWed by PCR as
described in methods using iNOS gene speciWc primers
and the sequence obtained submitted to GenBank
(Accession No.: AY211532). The cDNA produced
encodes the full-length iNOS protein when inserted into
the multiple cloning site of the pEGP-N1 plasmid and
driven by the CMV promoter of the plasmid. The Wrst
six bases at the 5 end of the cDNA produced were notTE
D P
RO
OF
part of the iNOS sequence. Instead, these six bases con-
stituted the Kozak consensus translation initiation site
for iNOS. The remaining sequence represents that for
iNOS. Sequence comparison revealed our cloned iNOS
cDNA to be highly homologous (>99.5%) with two
other published rat iNOS sequences, showing 17 single-
base mismatches to that published by Nunokawa et al.
[26, Accession No.: D14051], and 13 single-base mis-
matches to the sequence published by Geng et al. [27,
Accession No.: X76881]. These small diVerences occur
as sporadically placed amino acid substitutions (Fig. 1)
with no insertion or deletion mutations being apparent
between the clones. Our cDNA also shows a high level
of homology at the cDNA level to the inducible enzyme
from human [28] and mouse [29]. It contains a single
open reading frame beginning with an AUG methio-
nine at codon 1 and encodes a protein of 1147 residues
with a calculated molecular mass of 130.67 kDa. It also
contains the predicted consensus recognition sites for
the various cofactors including FMN (at amino acids:
620–639), FAD-PPi (at amino acids: 764–777), FAD-
ISO (at amino acids: 900–910), NADPH–Ribose (at
amino acids: 973–992), and NADPH-Ade (at amino
acids: 1074–1088) in the C-terminal and for calmodu-
line (at amino acids 502–527) in the mid portion. Fol-
lowing sequencing and analysis, the fragment produced
was subsequently subcloned into the HindIII and SacII
sites of the pEGFP-N1 vector and used in expression
studies.
EYciency of transfection of iNOS using peptide 6
Transfection of HEK-293 cells with iNOS-pEGFP-
N1 using peptide 6 under optimised conditions reported
previously [22] resulted in detectable expression of GFP
in 60–70% of cells. As shown in Fig. 2, visualisation of
transfected cells by Xuorescence microscopy conWrms
signiWcant expression of GFP at 6 h (Fig. 2A) with levels
increasing over time, reaching a peak at 24–48 h (Fig.
2D) but declining by 72 h due to marked decreases in cell
viability (data not shown).
Western blot analysis of lysates carried out in parallel
reXects a time-dependent expression of GFP which as
shown in Fig. 3A, was detectable after 6 h, peaking at
24 h. Expression of iNOS was evident after 6 h and was
maximal at 12 h remaining at this level over the 48 h
incubation period (Fig. 3B).
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3Fig. 1. Sequence analysis of rat iNOS highlighting random amino acid substitutions between our clone (clone 1, Accession No.: AY211532) and that
published by Nunokawa et al. (clone 2; Accession No.: D14051), and by Geng et al. (clone 3; Accession No.: X76881).
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ated by iNOS, additional experiments were carried out
Fig. 2. Expression of iNOS-EGFP in HEK293 cells. Cells were transfected with pEGFP-N1 harbouring the iNOS cDNA construct as described in
Experimental procedure. Cells were visualised at 6 h (A), 12 h (B), 24 h (C), and 48 h (D) after transfection using a Nikon EFD3, LABOPHOT-2 Xuo-
rescence microscope. These pictures are representative of observations made in at least three diVerent experiments.
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EVects of iNOS expression on nitrite production
Transfection of cells with iNOS-pEGFP-N1, but not
with empty or pEGFP-N1 vector, resulted in the expres-
sion of iNOS (Fig. 3B) and a marked increase in NO
production which was reXected in a time-dependent
increase in accumulated nitrite levels in the culture
medium (Fig. 4A). Moreover the maximum amount of
NO produced (56 § 0.03 pmolg protein¡1 nitrite at
48 h) was well within the range detected following induc-
tion of iNOS in various cells systems using inXammatory
mediators such as bacterial lipopolysaccharide and/or
cytokines. To conWrm that the detected nitrite is gener-
Fig. 3. Time course of expression of GFP (A) and iNOS (B) in trans-
fected HEK-293 cells. Lysates were obtained from control cells (lane
1) and at 6 h (lane 2), 12 h (lane 3), 24 h (lane 4), and 48 h (lane 5) after
transfection with iNOS-pEGFP-N1. Proteins were separated by SDS–
PAGE electrophoresis and probed with either a monoclonal anti-GFP
or anti-iNOS antibody as described in Experimental procedure. These
blots are representative of three separate experiments using three
diVerent batches of cells.Tin which transfected cells were co-incubated with thehighly selective iNOS inhibitor GW274150. As shown in
Fig. 5A, accumulated nitrite production was abolished
by 10M GW274150, conWrming iNOS as the source of
the NO produced.
EVects of iNOS expression on L-arginine transport
HEK-293 cells transported L-[3H]arginine in a time-
dependent manner which was linear over 5 min in both
transfected and non-transfected cells (data not shown).
As a result all subsequent uptake studies were carried
out over 1 min. The rate of uptake in 48 h controls was
1.91 § 0.03 pmolg protein¡1 min¡1 and there was no sig-
niWcant change in transporter activity in NO-generating
transfected cells expressing iNOS (Fig. 4B). Inhibition of
NO synthesis with GW274150 did not cause any signiW-
cant change in transport (Fig. 5B). Transfection of cells
with empty (data not shown) or pEGFP-N1 vector alone
did not alter L-arginine transport (Fig. 4B).
ProWle of CAT expression and activity in HEK-293 cells
Total RNA isolated from HEK-293 cells was probed
by RT-PCR for CAT-1, CAT-2A, and CAT2B using iso-
form speciWc primers. The data obtained show that
HEK-293 cells express the high aYnity CAT 1 and CAT
2B but not the low aYnity CAT 2 A (Fig. 6).
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In kinetic studies, entry of L-arginine was monitored
over the concentration range 5–1000M. Transport was
found to be saturable (Fig. 7) with a Km of 0.21 mM and
Vmax of 5.3 nmolg protein
¡1 min¡1 and occurred via a
single carrier system as evident from the Eadie–Hofstee
plot in Fig. 7 (inset).
In competition experiments the substrate speciWcity
of L-arginine transport was examined by screening the
inhibitory eVects of a series of 1 mM unlabelled amino
acids on uptake of 0.1 mM L-[3H]arginine. As shown in
Table 1, transport of L-arginine was unaVected by selec-
tive substrates for system A (preferred substrate: 2-
methylaminoisobutyric acid (MeAIB; [30]), ACS (pre-
ferred substrate: L-serine, L-alanine [31]), L (preferred
substrate: 2-aminobicyclo-(2,2,1)heptane-2-carboxylic
acid (BCH, [32]), and N (preferred substrate: 6-diazo-5-
oxo-L-norleucine (DON, [33]) but signiWcantly inhibited
by other cationic amino acids, L-lysine and L-ornithine
Fig. 4. EVects of iNOS-pEGFP-N1 transfection on NO production (A)
and L-arginine transport (B) in HEK-293 cells. Nitrite and transport
were measured at 6–48 h after transfection. Open bars represent con-
trol non-transfected cells, solid black bars represent cells transfected
with a GFP only vector and hatched bars represent cells transfected
with iNOS-pEGFP-N1. Results represent means § SEM of four sepa-
rate experiments with six replicates in each.TE
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(Table 1). In addition, transport was found to be
unaVected by changes in extracellular Na+ or pH rang-
ing from 6 to 7.4 (Table 2).
Fig. 5. EVect of GW274150 on NO production (A) and L-arginine
transport (B) in control and iNOS-pEGFP-N1 transfected HEK-293
cells. Nitrite and transport were measured 48 h after transfection.
Results represent means § SEM of three separate experiments with
two replicates in each.
Fig. 6. CAT expression in HEK-293 cells. Total RNA was isolated
from control, non-activated cells and RT-PCR performed (33 cycles)
using primer pairs speciWc for CAT-1, CAT-2A, and CAT-2B as out-
lined in Experimental procedure. Lanes represent: 1 D ladder,
2 D CAT-2A, 3 D CAT-2B, and 4 D CAT-1.
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Discussion
Production of NO by iNOS in several cell systems
depends critically on the availability and transport of L-
arginine. More importantly, the expression of iNOS
under these conditions is accompanied by a parallel
upregulation in L-arginine transporter activity. This
widely reported phenomenon [7,12,13,34–36] provides a
mechanism for sustaining substrate supply during
Fig. 7. Kinetics of L-arginine transport in HEK-293 cells. Rates of L-
arginine transport (0.005–2 mM) were measured in control cells. The
inset shows an Eadie–Hofstee plot of saturable transport, where V is
the initial velocity (pmol g protein¡1 min¡1) and S is the substrate
concentration (mM). Values are means § SEM of three diVerent
experiments with six replicates in each.
Table 1
Selectivity of L-arginine transport in control HEK-293 cells
Transport of 100 M L-arginine was measured over 1 min in the
absence or presence of a 10-fold excess (1 mM) of a given inhibitor.
Data are expressed as a percentage of the respective control inXux in
controls. Values are means § SE of three diVerent experiments with six
replicates in each.
* P < 0.01 relative to control.
Condition Transport rate (pmol g protein¡1 min¡1)
Control 2.09 § 0.10
System A/ASC substrates
MeAIB 2.56 § 0.14
Alanine 2.57 § 0.12
Serine 2.33 § 0.11
Proline 2.03 § 0.09
System N substrates
DON 1.74 § 0.08
L-Histidine 2.06 § 0.06
System L substrates
BCH 1.96 § 0.13
L-Phenylalanine 2.36 § 0.10
L-Leucine 1.85 § 0.13
System y+ substrates
L-Arginine 0.61 § 0.05*
L-Lysine 0.91 § 0.05*
L-Ornithine 0.97 § 0.09*TE
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enhanced synthesis of NO, and is thus a key target for
regulating NO synthesis by iNOS. Previous work has,
however, not determined whether the increase in trans-
porter activity is a direct consequence of increased iNOS
activity resulting in enhanced substrate uptake into the
cells.
To resolve this question we have examined whether
transiently expressing iNOS in non-induced cells can
regulate the rate of L-arginine transport as a conse-
quence of the increased utilisation of the amino acid for
NO synthesis. These studies were carried out in HEK-
293 cells transfected with an iNOS construct in pEGFP-
N1 vector using a synthetic peptide comprising of an
integrin-targeting (51 integrin selective) arginine-gly-
cine-aspartic acid tripeptide motif and a DNA-binding
moiety of 16 lysine residues [22]. This novel transfection
strategy resulted in consistently high transfection
eYciency where 750% of cells appeared transfected.
More importantly, the levels of iNOS protein expressed
and the amounts of NO produced were comparable to
those detected in various cell systems following induc-
tion with pro-inXammatory mediators [7,10,13,35,36].
This Wnding validates the use of peptide 6 as an eVective
nonviral system for iNOS gene transfer in HEK-293
cells.
However, despite the prominent expression of iNOS
and marked production of NO achieved, parallel trans-
port studies failed to show any modiWcation of L-argi-
nine transport: the transport rate in transfected cells was
not signiWcantly diVerent when compared to rates deter-
mined in control non-transfected cells. This observation
demonstrates that the expression of iNOS alone is not
suYcient to upregulate L-arginine uptake into cells. In
this regard, we and others have demonstrated that
increases in L-arginine transport are sensitive to inhibi-
tion by cycloheximide and associated with a marked
increase in the expression of transcripts for CATs, indi-
cating a critical requirement for protein synthesis of the
L-arginine transporter itself [7,14,15,20,21].
Table 2
EVects of Na+ and pH on L-arginine transport in HEK-293 cells
Transport of 100 M L-arginine was measured over 1 min in the pres-
ence (normal Krebs solution) or absence of Na+ and at varying pH
values ranging from pH 7.4 to pH 6). Data are expressed as a percent-
age of the respective control inXux in controls. Values are means § SE
of three diVerent experiments with six replicates in each.
Condition Transport rate (pmol g protein¡1 min¡1)
Na+-dependency
Control
+Na+ 1.8 § 0.11
¡Na+ 1.6 § 0.10
pH-dependency
7.4 (control) 1.85 § 0.08
7.0 1.89 § 0.11
6.5 1.86 § 0.06
6.0 1.82 § 0.12
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Our results therefore provide the Wrst direct evidence
that expression of active iNOS is by itself insuYcient to
upregulate CAT function and hence arginine transport.
This conclusion is apparently in conXict with a recent
report by Hammermann et al. [18], which suggests that
direct inhibition of iNOS activity in rat alveolar macro-
phages is suYcient to abolish LPS-activated L-arginine
uptake. The inhibitor of iNOS primarily used in those
experiments (AMT) did not inhibit basal arginine inXux
in control cells but inhibited enhanced arginine uptake
in LPS-pretreated cells even with brief pre-incubations.
The authors therefore concluded that this was an indi-
rect eVect due to reduced arginine utilisation by iNOS.
This association is however questionable since L-arginine
transport: (i) occurs by facilitated diVusion driven by the
membrane potential, (ii) accumulates L-arginine against
a concentration gradient, and (iii) is sensitive to trans-
stimulation when substrate concentrations are high on
the opposite side of the cell membrane [37,38]. Thus, if
inhibition of L-arginine utilisation by iNOS results in ele-
vated intracellular levels of this amino acid, entry of
radiolabelled L-arginine would be enhanced via trans-
stimulation causing an increase in L-[3H]arginine uptake.
As we observed no signiWcant changes in accumulated L-
[3H]arginine in cells transfected with our iNOS con-
struct, we conclude that activation of iNOS itself does
not inXuence rates of L-arginine transport. It could be
argued that in the system used by Hammermann et al.
[18], activation of cells may result in the co-induction of
linker proteins which may facilitate compartmentalised
regulation of L-arginine transport and NO synthesis.
This, however, still remains to be established and the
coupling of L-arginine transport to NO synthesis may
not be a widespread phenomenon in all activated cell
types [13,20,21].
DiVerences in the proWle of expression of L-arginine
transporter systems may explain the discrepancy
between our study and those of Hammermann et al. [18].
This latter point is important since there are suggestions
in the literature that CATs may be linked to diVerent
NOS enzymes, thereby providing a direct supply of sub-
strate for that isoform. In this regard, CAT-1 is thought
to supply substrate to endothelial NOS by virtue of its
co-localisation with this enzyme [39]. CAT-2B on the
other hand may regulate supply of L-arginine to iNOS as
these proteins are co-induced in cells where neither is
constitutively expressed. Moreover, in such systems, the
induction of CAT-2B can be accompanied by a parallel
downregulation in CAT-1 mRNA [14], thereby making
CAT-2B the critical transporter in these cells.
Since the nature of the transporters associated with L-
arginine uptake had not previously been characterised in
HEK-293 cells, we have therefore examined the charac-
teristics of L-arginine transport and the proWle of expres-
sion of CATs in these cells. Kinetic studies and Eadie–
Hofstee analysis show that entry of L-arginine occursTE
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predominantly via a single saturable carrier that is of rel-
atively low capacity but of high aYnity for L-arginine.
Transport was selectively inhibited by the cationic
amino acids L-lysine, L-ornithine, and by L-arginine itself.
Substrates for amino acid transport systems A/ASC, N,
and L were without signiWcant eVect. This inhibition
proWle together with the Na+ and pH insensitivity
strongly implicate the CATs as the predominant carrier
of L-arginine in HEK-293 cells and excludes other sys-
tems such as y+L, bo,+, and Bo,+ which are broad scope in
nature, transporting both cationic and neutral amino
acids [38,40].
To identify the CAT or CATs expressed in HEK-293
cells we carried out RT-PCR of total RNA isolated from
these cells using CAT-1, CAT-2A, and CAT-2B-speciWc
primers respectively. CAT-3 was not investigated since
this transporter is thought to be expressed predomi-
nantly in brain [41,42] and thymus tissue [43] and also
interacts with neutral amino acids [41]. The data
obtained show that HEK-293 cells express transcripts
for CAT-1 and CAT-2B but not for CAT-2A. This
expression proWle agrees with the functional studies in
that the kinetics of uptake reXects a high aYnity system
or systems with indistinguishable characteristics at the
functional level. Although, CAT-2A and CAT-2B are
spliced variants with high percentage structural homol-
ogy they are functionally distinguishable by virtue of the
fact that CAT-2A is a high capacity but low aYnity car-
rier while CAT-2B exhibits similar functional character-
istics to those of CAT-1 [44–46]. Both these carriers have
a high aYnity for L-arginine, transporting the latter with
a Michaelis constant (Km) of between 0.14 and 0.38 mM.
The Km of 0.21 mM determined in our study therefore
supports CAT-1 and CAT-2B as being the predominant
carriers of L-arginine into HEK-293 cells.
At present we cannot distinguish between CAT-1 and
CAT-2B in terms of their relative contribution to total L-
arginine uptake nor can we specify which CAT directly
supplies L-arginine to transfected iNOS in our cell sys-
tem. However, the detection of CAT-2B transcripts, gen-
erally believed to be expressed under inXammatory
conditions in parallel with iNOS, suggests that this pro-
tein can exist endogenously in control conditions and
may not require induction. More importantly, its detec-
tion excludes the possibility that iNOS was not able to
alter transport in our studies because of lack of expres-
sion of the critical CAT (CAT-2B) associated with
uptake of L-arginine for utilisation by this enzyme.
In conclusion, our current Wndings provide the Wrst
direct evidence that CATs function independently of
iNOS and that the rate of transport of L-arginine into
cells is not modulated by the activity of iNOS. Thus, the
enhancement in L-arginine transport observed in systems
where expression of iNOS and the subsequent genera-
tion of large quantities of NO are induced must occur
via mechanisms not directly related to the rate of con-
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sumption of L-arginine or generation of NO by iNOS.
These mechanisms presumably involve activation by
external stimuli of common upstream signalling path-
ways leading to upregulation of iNOS and CAT expres-
sion [15].
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